James Hardie to sell Fermacell for €840m to Holcim
James Hardie will sell its European walling and flooring business, Fermacell, to Holcim for €840m. The company plans to close its European fibre cement business, focusing on North America. Proceeds will repay debt and fund a $250m share repurchase program. Holcim expects the deal to be earnings-accretive from 2027.
How this was made

The 30-second read
Why it matters
The transaction improves James Hardie's balance sheet and returns capital to shareholders, while Holcim gains a strategic product line.
Market read
A large‑scale M&A deal that reshapes the building‑materials landscape and offers immediate trading opportunities for both stocks.
What to watch
Potential integration challenges for Holcim and the impact of currency fluctuations on the €840 million price.
Background
James Hardie is refocusing on its North American business after criticism of its AZEK acquisition; Holcim seeks growth in European walling and flooring.
Ticker impact
James Hardie announced the sale of its European business Fermacell to Holcim for €840 million.
Potential upside of 3‑5% as debt reduction and buyback are priced in.
The deal is sizable, improves balance sheet, and signals focus on North America.
Market effects
Consolidation in the building‑materials sector may pressure peers to consider similar divestitures or acquisitions.
European construction material markets could see a shift in competitive dynamics as Holcim expands its footprint.
The deal highlights a trend of North‑American focused firms shedding European assets, influencing cross‑border M&A sentiment.
Counterpoint
The sale may signal underlying weakness in James Hardie's European operations, suggesting further downside risk.
Key entities
- CompanyJames Hardie
Fibre‑cement manufacturer listed on NYSE (JHX).
- CompanyHolcim
Swiss building‑materials supplier with ADR listed on NYSE (HLG).